Namenda Xr

Dementia, Vascular, Dementia, Vascular, Alzheimer's Disease + 3 more

Treatment

4 FDA approvals

20 Active Studies for Namenda Xr

What is Namenda Xr

Memantine

The Generic name of this drug

Treatment Summary

Memantine is a medication used to treat Alzheimer’s Disease. It works differently from other Alzheimer’s medications by blocking glutamate, a chemical in the brain which can cause excessive stimulation in Alzheimer’s Disease. The drug was approved by the FDA in 2013 and the number of people living with Alzheimer’s Disease worldwide has been steadily increasing since then. In 2013, the G8 dementia summit concluded that dementia should be a priority and that a cure or a disease-modifying therapy should be developed by 2025.

Namenda

is the brand name

image of different drug pills on a surface

Namenda Xr Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Namenda

Memantine

2003

235

Approved as Treatment by the FDA

Memantine, commonly known as Namenda, is approved by the FDA for 4 uses like Alzheimer's Disease and moderate Alzheimer's Type Dementia .

Alzheimer's Disease

Used to treat moderate Alzheimer's Type Dementia in combination with Donepezil

moderate Alzheimer's Type Dementia

Used to treat moderate Alzheimer's Type Dementia in combination with Donepezil

severe Alzheimer's Type Dementia

Helps manage severe Alzheimer's Type Dementia

Alzheimer's Disease

Helps manage severe Alzheimer's Type Dementia

Effectiveness

How Namenda Xr Affects Patients

Memantine helps to improve Alzheimer's dementia symptoms such as cognition. At lower doses, it can help with memory and protect neurons from damage caused by certain neurotransmitters. It does not interact with most other receptors, such as those for GABA, dopamine, or adrenaline. In lab studies, it has been shown not to interfere with medications such as donepezil, galantamine, or tacrine.

How Namenda Xr works in the body

Memantine is used to treat Alzheimer's disease by blocking overactive N-methyl-D-aspartate (NMDA) receptors in the brain. These receptors are normally stimulated by a chemical called glutamate, but too much of it can be toxic to the brain. Memantine stops glutamate from overstimulating these receptors, thus preventing neurotoxicity. While this is not a cure for Alzheimer's, it can help slow down the neurodegeneration associated with the disease.

When to interrupt dosage

The measure of Namenda Xr is contingent upon the diagnosed sickness, including Alzheimer's Disease, Alzheimer's Disease and Dementia, Vascular. The dosage amount further varies as per the strategy of delivery (e.g. Kit - Oral or Solution - Oral) featured in the table beneath.

Condition

Dosage

Administration

Alzheimer's Disease

, 5.0 mg, 10.0 mg, 2.0 mg/mL, 7.0 mg, 14.0 mg, 28.0 mg, 20.0 mg, 5.0 mg/pump actuation, 21.0 mg, 10.0 mg/mL, 15.0 mg, 70.0 mg

Oral, , Tablet, Tablet - Oral, Kit, Kit - Oral, Solution - Oral, Solution, Tablet, film coated, Tablet, film coated - Oral, Capsule, extended release - Oral, Capsule, extended release, Capsule - Oral, Capsule, Liquid - Oral, Liquid, Tablet, coated, Tablet, coated - Oral

Alzheimer's Disease

, 5.0 mg, 10.0 mg, 2.0 mg/mL, 7.0 mg, 14.0 mg, 28.0 mg, 20.0 mg, 5.0 mg/pump actuation, 21.0 mg, 10.0 mg/mL, 15.0 mg, 70.0 mg

Oral, , Tablet, Tablet - Oral, Kit, Kit - Oral, Solution - Oral, Solution, Tablet, film coated, Tablet, film coated - Oral, Capsule, extended release - Oral, Capsule, extended release, Capsule - Oral, Capsule, Liquid - Oral, Liquid, Tablet, coated, Tablet, coated - Oral

Dementia, Vascular

, 5.0 mg, 10.0 mg, 2.0 mg/mL, 7.0 mg, 14.0 mg, 28.0 mg, 20.0 mg, 5.0 mg/pump actuation, 21.0 mg, 10.0 mg/mL, 15.0 mg, 70.0 mg

Oral, , Tablet, Tablet - Oral, Kit, Kit - Oral, Solution - Oral, Solution, Tablet, film coated, Tablet, film coated - Oral, Capsule, extended release - Oral, Capsule, extended release, Capsule - Oral, Capsule, Liquid - Oral, Liquid, Tablet, coated, Tablet, coated - Oral

Dementia, Vascular

, 5.0 mg, 10.0 mg, 2.0 mg/mL, 7.0 mg, 14.0 mg, 28.0 mg, 20.0 mg, 5.0 mg/pump actuation, 21.0 mg, 10.0 mg/mL, 15.0 mg, 70.0 mg

Oral, , Tablet, Tablet - Oral, Kit, Kit - Oral, Solution - Oral, Solution, Tablet, film coated, Tablet, film coated - Oral, Capsule, extended release - Oral, Capsule, extended release, Capsule - Oral, Capsule, Liquid - Oral, Liquid, Tablet, coated, Tablet, coated - Oral

Alzheimer's Disease

, 5.0 mg, 10.0 mg, 2.0 mg/mL, 7.0 mg, 14.0 mg, 28.0 mg, 20.0 mg, 5.0 mg/pump actuation, 21.0 mg, 10.0 mg/mL, 15.0 mg, 70.0 mg

Oral, , Tablet, Tablet - Oral, Kit, Kit - Oral, Solution - Oral, Solution, Tablet, film coated, Tablet, film coated - Oral, Capsule, extended release - Oral, Capsule, extended release, Capsule - Oral, Capsule, Liquid - Oral, Liquid, Tablet, coated, Tablet, coated - Oral

Alzheimer's Disease

, 5.0 mg, 10.0 mg, 2.0 mg/mL, 7.0 mg, 14.0 mg, 28.0 mg, 20.0 mg, 5.0 mg/pump actuation, 21.0 mg, 10.0 mg/mL, 15.0 mg, 70.0 mg

Oral, , Tablet, Tablet - Oral, Kit, Kit - Oral, Solution - Oral, Solution, Tablet, film coated, Tablet, film coated - Oral, Capsule, extended release - Oral, Capsule, extended release, Capsule - Oral, Capsule, Liquid - Oral, Liquid, Tablet, coated, Tablet, coated - Oral

Warnings

Namenda Xr has a single contraindication. If you are afflicted with any of the ailments given in the table below, Namenda Xr should not be utilized.

Namenda Xr Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Memantine may interact with Pulse Frequency

There are 20 known major drug interactions with Namenda Xr.

Common Namenda Xr Drug Interactions

Drug Name

Risk Level

Description

Acenocoumarol

Major

The metabolism of Acenocoumarol can be decreased when combined with Memantine.

Amitriptyline

Major

The metabolism of Amitriptyline can be decreased when combined with Memantine.

Antipyrine

Major

The metabolism of Antipyrine can be decreased when combined with Memantine.

Apomorphine

Major

The metabolism of Apomorphine can be decreased when combined with Memantine.

Artemether

Major

The metabolism of Artemether can be decreased when combined with Memantine.

Namenda Xr Toxicity & Overdose Risk

The toxic dose of memantine in mice is 437-498 mg/kg and in rats is 328-370 mg/kg. No evidence of cancer or genetic damage was found in mice and rats given the drug. There were also no effects on fertility or reproductive performance in animals given the drug. Memantine is a pregnancy category B drug, meaning that it has not been adequately studied in pregnant women and should only be used if the potential benefits outweigh the possible risks to the fetus. It is unknown if memantine is passed into breast milk, so caution should be taken when it is used by nursing mothers.

image of a doctor in a lab doing drug, clinical research

Namenda Xr Novel Uses: Which Conditions Have a Clinical Trial Featuring Namenda Xr?

41 active studies are assessing the potential of Namenda XR to provide therapeutic benefit for Alzheimer's Disease, Dementia, Vascular and Alzheimer's Disease-related conditions.

Condition

Clinical Trials

Trial Phases

Alzheimer's Disease

3 Actively Recruiting

Phase 3, Phase 2

Alzheimer's Disease

0 Actively Recruiting

Alzheimer's Disease

39 Actively Recruiting

Phase 4, Phase 2, Phase 3, Not Applicable, Phase 1

Dementia, Vascular

0 Actively Recruiting

Alzheimer's Disease

0 Actively Recruiting

Dementia, Vascular

0 Actively Recruiting

Namenda Xr Reviews: What are patients saying about Namenda Xr?

5

Patient Review

1/16/2017

Namenda Xr for Moderate to Severe Alzheimer's Type Dementia

My husband takes the XR and Aricept together, and they work really well for him. He's able to function normally but doesn't have much energy or enthusiasm. I think he's just being lazy, but I understand that it's a side effect of his illness.

4

Patient Review

3/12/2014

Namenda Xr for Moderate to Severe Alzheimer's Type Dementia

This treatment can cause a decrease in muscle strength.

3.7

Patient Review

3/13/2014

Namenda Xr for Moderate to Severe Alzheimer's Type Dementia

I've been on this medication for three weeks and I've noticed that after taking it for six hours, I feel an urge to clean. Afterward, however, I become very sleepy. Additionally, I sometimes have nightmares; though they're not too bad. Overall, this drug has helped me more than it's hurt me.

3.3

Patient Review

6/3/2016

Namenda Xr for Moderate to Severe Alzheimer's Type Dementia

It's hard to say for certain.

2.3

Patient Review

8/23/2015

Namenda Xr for Moderate to Severe Alzheimer's Type Dementia

This medication caused my mother to regress; she stopped eating and her days and nights were reversed. She was also constantly crying, tearful, confused, and seeing things that weren't there. I had to take her off the medication immediately, but thankfully she's doing much better now.

1.3

Patient Review

2/18/2014

Namenda Xr for Moderate to Severe Alzheimer's Type Dementia

My dad has been taking this medication and it's made him want to sleep all the time. He's much more sedentary now and isn't able to do tasks he could before. This is really tough on my mom who is his primary caregiver. I think they're going to talk to the doctor about taking him off the medication soon.

1

Patient Review

7/10/2015

Namenda Xr for Moderate to Severe Alzheimer's Type Dementia

Since my mother started this medication, she's been having terrible nightmares and repeating herself constantly. I contacted her doctor and they said it wasn't the medicine, but I don't think that's true. This morning she thought people were in her room and when I told her she was dreaming, she didn't believe me. It's so sad to see what this has done to her.

1

Patient Review

8/11/2014

Namenda Xr for Moderate to Severe Alzheimer's Type Dementia

I was prescribed this drug for my migraines, and it's helped lower the frequency with which I experience them.

1

Patient Review

8/10/2015

Namenda Xr for Moderate to Severe Alzheimer's Type Dementia

My husband became very confused and disoriented after only four days on this medication. He stopped taking it immediately, and within 10 days was back to his old self. We were both very relieved. I would not recommend this drug to anyone.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about namenda xr

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does Namenda XR do for you?

"Namenda XR is a prescription medication used to treat moderate to severe dementia related to Alzheimer's disease. It works by reducing the amount of a certain chemical in the brain that can contribute to dementia symptoms."

Answered by AI

Should Namenda be taken in the morning or at night?

"It doesn't matter what time of day you take memantine, as long as you are consistent with the timing. Try to take your doses at the same time every day."

Answered by AI

Is there a generic for Namenda XR?

"sees Amneal and Lupin releasing their own AB-rated generic versions of Allergan's Namenda XR. Mylan and Sun had received FDA approval for their own generic Namenda XR on September 28, 2016."

Answered by AI

What are side effects of Namenda?

"The flu can cause a range of symptoms, including fatigue, muscle aches, joint pain, dizziness, nausea, vomiting, diarrhea, and constipation."

Answered by AI

Clinical Trials for Namenda Xr

Image of Weill Cornell Medicine Brain Health Imaging Institute in New York, United States.

Leronlimab for Alzheimer's Disease

18+
All Sexes
New York, NY

The present study will administer the drug leronlimab to 20 participants who are above 50 years old with Alzheimer's disease (AD) or mild cognitive impairment due to AD. While leronlimab is considered safe in other diseases like Human Immunodeficiency Virus (HIV) and certain types of breast cancer, its safety and tolerability in AD will be tested for the first time. The main purpose of this study is to learn: 1. Is this drug safe for participants with AD and MCI due to AD? 2. Does leronlimab change levels of brain inflammation? The results of this study could lead to future studies with more participants that will test whether leronlimab may slow or prevent the decline in thinking abilities and brain function in this group of participants. Using leronlimab for Alzheimer's disease is experimental, which means that the Food and Drug Administration (FDA) has not approved Leronlimab for this purpose. Participants will be asked to take leronlimab once a week for 12 weeks in our clinic or in their own home. Participants will also be asked to complete the below procedures before and after taking leronlimab for 12 weeks: 1. Undergo 2 types of brain scans, Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI). 2. Visit our clinic for routine lab work, an electrocardiogram (ECG), and a physical exam. 3. Donate blood so the researchers can better understand how leronlimab affects levels of inflammation and proteins related AD in the blood. 4. Undergo a series of tests and questionnaires that test thinking abilities. 5. Have weekly phone calls with researchers to let them know if there are side effects will taking this drug.

Phase 2
Waitlist Available

Weill Cornell Medicine Brain Health Imaging Institute

Tracy A Butler, MD

Image of The Feinstein Institutes for Medical Research in Manhasset, United States.

WeCareToFeedDysphagia Tool for Caregiver Burden in Dementia

18+
All Sexes
Manhasset, NY

The goal of this clinical trial is to learn if a newly-created website tool, called WeCareToFeedDysphagia, helps to reduce feelings of burden in care partners of patients with Alzheimer's disease and related dementias (AD/ADRD) who were diagnosed with trouble swallowing (oropharyngeal dysphagia). The main questions this study aims to answer are: * How effective is the WeCareToFeedDysphagia tool in reducing feelings of burden in care partners? * Does the WeCareToFeed Dysphagia tool help improve patient outcomes? * Does care partner age, gender, and patient dysphagia severity impact the strength of the effect of the WeCareToFeedDysphagia tool? * Is the strength of the effect of the WeCareToFeedDysphagia tool impacted by care partner's beliefs in being able to manage behavior and stress (self-efficacy)? Researchers will compare a group of care partners who have access to the WeCareToFeedDysphagia tool (intervention) to a group of care partners who do not have access to the tool. Both groups will receive contact information for help from a speech language pathologist expert (enhanced usual care). Participants will: * be given access to the web tool and receive 3 text message reminders over 3 weeks to use the tool (intervention group only). * be asked to complete a remote, web-based survey three times: when enrolled in the study, at 1 month following patient leaving the hospital, and at 3 months following patient leaving the hospital.

Waitlist Available
Has No Placebo

The Feinstein Institutes for Medical Research

Liron Sinvani, MD

Image of CSMC in Los Angeles, United States.

Photobiomodulation for Alzheimer's Disease

55 - 89
All Sexes
Los Angeles, CA

The purpose of this study is to see if a special light treatment, called photobiomodulation, can help people with memory problems such as Mild Cognitive Impairment or Mild Dementia due to Alzheimer's disease. The light is given to the forehead using an FDA-cleared medical device. This device is cleared to provide topical heating to elevate tissue temperature for temporary relief of muscle and joint pain, muscle spasm and stiffness associated with arthritis. It also increases blood circulation and relaxes muscle tissue. This device is being used "off-label," meaning it will be used in a way that is different than its cleared use. We want to learn whether this light treatment can improve executive function, and whether it changes certain inflammatory and neurodegeneration related signals in the blood. To do this, we will apply the photobiomodulation device to your forehead. We will also ask you questions and give you cognitive tests before and after light treatment. We will also collect blood samples before and after treatment.

Recruiting
Device

CSMC

Golnaz Yadollahikhales, MD

Have you considered Namenda Xr clinical trials?

We made a collection of clinical trials featuring Namenda Xr, we think they might fit your search criteria.
Go to Trials

Have you considered Namenda Xr clinical trials?

We made a collection of clinical trials featuring Namenda Xr, we think they might fit your search criteria.
Go to Trials

Have you considered Namenda Xr clinical trials?

We made a collection of clinical trials featuring Namenda Xr, we think they might fit your search criteria.
Go to Trials